Gaucher Disease Treatment Market Size and Share 2019 | Growth Analysis, Application, Leading Players, Future Insights and Global Industry Trends By 2026
Gaucher disease is an autosomal recessive inherited metabolism disorder that is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme which result into degradation of glucocerebroside. They can be classified into type 1, type 2, and type 3. Out of which, type 1 is the most common type of Gaucher disease.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1225
Approval of a novel drug is projected to propel the market growth of Gaucher disease treatment market
U.S. Food and Drug Administration (FDA) has approved multiple drugs in the last few years for the treatment of disease. In 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 Gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by the FDA for type 1 Gaucher disease. These drugs offer a variety of options based on their requirements, which in turn is expected to boost the growth of the market.
In July 2017, The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) collaborated to promote the use of innovative approaches in the development of medicines for Gaucher disease. Such a strategic collaboration of regulatory bodies for the development of novel innovative drugs is expected to boost the growth of the Gaucher disease treatment market in the near future. On the other hand, lack of awareness regarding the symptoms, diagnosis, and treatment of disease among the rural population is a major factor hampering the market growth.
The Gaucher disease treatment market is segmented based on disease type, treatment type, and distribution channel.
Based On Disease Type
- Type 1 Gaucher disease
- Type 2 Gaucher disease
- Type 3 Gaucher disease
Based On Therapy Type
- Enzyme Replacement Therapy (ERT)
- Substrate Reduction Therapy (SRT)
Based On The Distribution Channel
- Retail Pharmacies
- Online Pharmacies
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3bOYTiU
North America is projected to hold a dominant position owing to rising research activities and drug development for Gaucher disease
North America is expected to hold the dominant position in the Gaucher disease treatment market owing to the rising number of research activities for the development of novel drugs. In 2016, the scientist from the National Institutes of Health researchers collaborated with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS). Researchers identified a new molecule that offers a promising approach for the treatment of the rare Gaucher disease. Followed by Europe is expected to be the second-largest market for Gaucher disease treatment and this can be attributed to the initiative taken by European organizations to spread awareness regarding Gaucher disease among the population. For instance, in 2014, the European Gaucher Alliance launched Gaucher Awareness Day aims to spread awareness about this rare disease among the European population.
Key players operating in the global Gaucher disease treatment market include Genzyme Corporation, Pfizer, Inc., Shire Human Genetic Therapies, Inc., and Actelion Pharmaceuticals Ltd. (acquired by Johnson & Johnson in June 2017). There are various drugs in the pipeline of companies such as Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV, and Orphazyme ApS, for Gaucher disease treatment.
Need a discount?
Note: *The discount is offered on the Standard Price of the report.
Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1225
Table of Content
Global Gaucher Disease Treatment Market Research Report
Section 1: Global Gaucher Disease Treatment Industry Overview
Section 2: Global Economic Impact on Gaucher Disease Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Gaucher Disease Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Gaucher Disease Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire